Reuters logo
BRIEF-New GSK CEO likely to give strategy update in H2 2017
February 8, 2017 / 12:53 PM / in 8 months

BRIEF-New GSK CEO likely to give strategy update in H2 2017

Feb 8 (Reuters) - Outgoing GlaxoSmithKline CEO Andrew Witty told reporters:

* 2017 outlook “very much” in line with market consensus

* Lot of common ground with Trump on FDA regulatory reform but need to ensure safety

* Accelerated drug approvals would give room for lowering drug prices

* Shame if EMA moves from London because will cause disruption

* Would be wise for UK to get significant mutual recognition with EMA on drug approvals

* New CEO Emma Walmsley likely to update investors on strategy in H2 2017 Further company coverage: (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below